Sutro Biopharma, Inc.
STRO
$7.30
-$0.72-8.95%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.77% | 147.98% | 33.76% | -86.98% | -49.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.77% | 147.98% | 33.76% | -86.98% | -49.66% |
| Cost of Revenue | -35.83% | -38.21% | -28.04% | -46.74% | 36.00% |
| Gross Profit | 43.72% | 170.00% | 53.70% | -19.79% | -86.43% |
| SG&A Expenses | -39.01% | -16.39% | 4.34% | -46.26% | -6.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.43% | -34.58% | -6.79% | 13.46% | 25.44% |
| Operating Income | 42.72% | 130.97% | 16.12% | -251.23% | -54.31% |
| Income Before Tax | -16.54% | 76.01% | -30.50% | -249.53% | -2.83% |
| Income Tax Expenses | -- | -325.00% | -- | -85.10% | -- |
| Earnings from Continuing Operations | -16.54% | 76.05% | -30.50% | -333.20% | 1.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.54% | 76.05% | -30.50% | -333.20% | 1.01% |
| EBIT | 42.72% | 130.97% | 16.12% | -251.23% | -54.31% |
| EBITDA | 44.04% | 136.20% | 16.89% | -241.23% | -56.40% |
| EPS Basic | -12.66% | 77.00% | 3.49% | -272.33% | 26.89% |
| Normalized Basic EPS | 36.93% | 112.55% | 34.37% | -232.86% | -11.22% |
| EPS Diluted | -12.66% | 77.00% | 3.49% | -272.33% | 26.89% |
| Normalized Diluted EPS | 36.93% | 112.55% | 34.37% | -232.86% | -11.22% |
| Average Basic Shares Outstanding | 3.44% | 4.13% | 35.22% | 35.33% | 35.39% |
| Average Diluted Shares Outstanding | 3.44% | 4.13% | 35.22% | 35.33% | 35.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |